APO Research
Talk to an analyst

APO RESEARCH · REPORT

Alpha L-Iduronidase

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Alpha L-Iduronidase Market Outlook and Growth Opportunities 2026

2 January 2026195 pages

Choose your research edition.

Industry ResearchAlpha L-Iduronidase Industry Research Report 2026124 pages · $2,950 USDIndustry Growth & TrendsGlobal Alpha L-Iduronidase Industry Growth and Trends Forecast to 2032109 pages · $3,450 USDMarket StructureGlobal Alpha L-Iduronidase Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032192 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Alpha L-Iduronidase Market Outlook and Growth Opportunities 2026195 pages · $4,250 USDMarket Analysis & ForecastGlobal Alpha L-Iduronidase Market Analysis and Forecast 2026-2032192 pages · $4,950 USD

Market perspective

The global Alpha L-Iduronidase market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Alpha L-Iduronidase is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Alpha L-Iduronidase is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Alpha L-Iduronidase is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Alpha L-Iduronidase market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Alpha L-Iduronidase market include ArmaGen Inc, BioStrategies LC, Denali Therapeutics Inc, EdiGene Inc, Gain Therapeutics Inc, Immusoft Corp, JCR Pharmaceuticals Co Ltd, Orchard Therapeutics Plc and Ossianix Inc, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Alpha L-Iduronidase market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Alpha L-Iduronidase and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Alpha L-Iduronidase sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Alpha L-Iduronidase market size, projected growth trends, production technologies, key applications, and end-use industries.

Alpha L-Iduronidase Segment by Company

ArmaGen Inc

BioStrategies LC

Denali Therapeutics Inc

EdiGene Inc

Gain Therapeutics Inc

Immusoft Corp

JCR Pharmaceuticals Co Ltd

Orchard Therapeutics Plc

Ossianix Inc

Rain Bio Inc

RegenxBio Inc

Tega Therapeutics Inc

Alpha L-Iduronidase Segment by Type

IDUA

EC 3.2.1.76

Alpha L-Iduronidase Segment by Application

Oncology

Dermatology

Immunology

Musculoskeletal Disorders

Alpha L-Iduronidase Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global Alpha L-Iduronidase status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Alpha L-Iduronidase market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Alpha L-Iduronidase significant trends, drivers, influence factors in global and regions.

6. To analyze Alpha L-Iduronidase competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Alpha L-Iduronidase market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Alpha L-Iduronidase and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Alpha L-Iduronidase.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Alpha L-Iduronidase market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Alpha L-Iduronidase industry.

Chapter 3: Detailed analysis of Alpha L-Iduronidase manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Alpha L-Iduronidase in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Alpha L-Iduronidase in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Alpha L-Iduronidase Industry Trends Table 2. Alpha L-Iduronidase Industry Drivers Table 3. Alpha L-Iduronidase Industry Opportunities and Challenges Table 4. Alpha L-Iduronidase Industry Restraints Table 5. Global Alpha L-Iduronidase Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Alpha L-Iduronidase Revenue Share by Company (2021-2026) Table 7. Global Alpha L-Iduronidase Sales Volume by Company (K Units) & (2021-2026) Table 8. Global Alpha L-Iduronidase Sales Volume Share by Company (2021-2026) Table 9. Global Alpha L-Iduronidase Average Price (US$/Unit) of Company (2021-2026) Table 10. Global Alpha L-Iduronidase Company Ranking, (2024-2026) & (USD Million) Table 11. Global Alpha L-Iduronidase Key Company Manufacturing Base & Headquarters Table 12. Global Alpha L-Iduronidase Company, Product Type & Application Table 13. Global Alpha L-Iduronidase Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Alpha L-Iduronidase by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of IDUA Table 18. Significant Companies of EC 3.2.1.76 Table 19. Global Alpha L-Iduronidase Sales Volume by Type 2021 VS 2025 VS 2032 (K Units) Table 20. Global Alpha L-Iduronidase Sales Volume by Type (2021-2026) & (K Units) Table 21. Global Alpha L-Iduronidase Sales Volume by Type (2027-2032) & (K Units) Table 22. Global Alpha L-Iduronidase Sales Volume Share by Type (2021-2026) Table 23. Global Alpha L-Iduronidase Sales Volume Share by Type (2027-2032) Table 24. Global Alpha L-Iduronidase Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 25. Global Alpha L-Iduronidase Sales Value by Type (2021-2026) & (US$ Million) Table 26. Global Alpha L-Iduronidase Sales Value by Type (2027-2032) & (US$ Million) Table 27. Global Alpha L-Iduronidase Sales Value Share by Type (2021-2026) Table 28. Global Alpha L-Iduronidase Sales Value Share by Type (2027-2032) Table 29. Significant Companies of Oncology Table 30. Significant Companies of Dermatology Table 31. Significant Companies of Immunology Table 32. Significant Companies of Musculoskeletal Disorders Table 33. Global Alpha L-Iduronidase Sales Volume by Application 2021 VS 2025 VS 2032 (K Units) Table 34. Global Alpha L-Iduronidase Sales Volume by Application (2021-2026) & (K Units) Table 35. Global Alpha L-Iduronidase Sales Volume by Application (2027-2032) & (K Units) Table 36. Global Alpha L-Iduronidase Sales Volume Share by Application (2021-2026) Table 37. Global Alpha L-Iduronidase Sales Volume Share by Application (2027-2032) Table 38. Global Alpha L-Iduronidase Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 39. Global Alpha L-Iduronidase Sales Value by Application (2021-2026) & (US$ Million) Table 40. Global Alpha L-Iduronidase Sales Value by Application (2027-2032) & (US$ Million) Table 41. Global Alpha L-Iduronidase Sales Value Share by Application (2021-2026) Table 42. Global Alpha L-Iduronidase Sales Value Share by Application (2027-2032) Table 43. Global Alpha L-Iduronidase Sales by Region: 2021 VS 2025 VS 2032 (K Units) Table 44. Global Alpha L-Iduronidase Sales by Region (2021-2026) & (K Units) Table 45. Global Alpha L-Iduronidase Sales Market Share by Region (2021-2026) Table 46. Global Alpha L-Iduronidase Sales by Region (2027-2032) & (K Units) Table 47. Global Alpha L-Iduronidase Sales Market Share by Region (2027-2032) Table 48. Global Alpha L-Iduronidase Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 49. Global Alpha L-Iduronidase Sales Value by Region (2021-2026) & (US$ Million) Table 50. Global Alpha L-Iduronidase Sales Value Share by Region (2021-2026) Table 51. Global Alpha L-Iduronidase Sales Value by Region (2027-2032) & (US$ Million) Table 52. Global Alpha L-Iduronidase Sales Value Share by Region (2027-2032) Table 53. Global Alpha L-Iduronidase Market Average Price (US$/Unit) by Region (2021-2026) Table 54. Global Alpha L-Iduronidase Market Average Price (US$/Unit) by Region (2027-2032) Table 55. Global Alpha L-Iduronidase Sales by Country: 2021 VS 2025 VS 2032 (K Units) Table 56. Global Alpha L-Iduronidase Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 57. Global Alpha L-Iduronidase Sales by Country (2021-2026) & (K Units) Table 58. Global Alpha L-Iduronidase Sales Market Share by Country (2021-2026) Table 59. Global Alpha L-Iduronidase Sales by Country (2027-2032) & (K Units) Table 60. Global Alpha L-Iduronidase Sales Market Share by Country (2027-2032) Table 61. Global Alpha L-Iduronidase Sales Value by Country (2021-2026) & (US$ Million) Table 62. Global Alpha L-Iduronidase Sales Value Market Share by Country (2021-2026) Table 63. Global Alpha L-Iduronidase Sales Value by Country (2027-2032) & (US$ Million) Table 64. Global Alpha L-Iduronidase Sales Value Market Share by Country (2027-2032) Table 65. ArmaGen Inc Company Information Table 66. ArmaGen Inc Business Overview Table 67. ArmaGen Inc Alpha L-Iduronidase Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 68. ArmaGen Inc Alpha L-Iduronidase Product Portfolio Table 69. ArmaGen Inc Recent Development Table 70. BioStrategies LC Company Information Table 71. BioStrategies LC Business Overview Table 72. BioStrategies LC Alpha L-Iduronidase Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 73. BioStrategies LC Alpha L-Iduronidase Product Portfolio Table 74. BioStrategies LC Recent Development Table 75. Denali Therapeutics Inc Company Information Table 76. Denali Therapeutics Inc Business Overview Table 77. Denali Therapeutics Inc Alpha L-Iduronidase Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 78. Denali Therapeutics Inc Alpha L-Iduronidase Product Portfolio Table 79. Denali Therapeutics Inc Recent Development Table 80. EdiGene Inc Company Information Table 81. EdiGene Inc Business Overview Table 82. EdiGene Inc Alpha L-Iduronidase Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 83. EdiGene Inc Alpha L-Iduronidase Product Portfolio Table 84. EdiGene Inc Recent Development Table 85. Gain Therapeutics Inc Company Information Table 86. Gain Therapeutics Inc Business Overview Table 87. Gain Therapeutics Inc Alpha L-Iduronidase Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 88. Gain Therapeutics Inc Alpha L-Iduronidase Product Portfolio Table 89. Gain Therapeutics Inc Recent Development Table 90. Immusoft Corp Company Information Table 91. Immusoft Corp Business Overview Table 92. Immusoft Corp Alpha L-Iduronidase Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 93. Immusoft Corp Alpha L-Iduronidase Product Portfolio Table 94. Immusoft Corp Recent Development Table 95. JCR Pharmaceuticals Co Ltd Company Information Table 96. JCR Pharmaceuticals Co Ltd Business Overview Table 97. JCR Pharmaceuticals Co Ltd Alpha L-Iduronidase Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 98. JCR Pharmaceuticals Co Ltd Alpha L-Iduronidase Product Portfolio Table 99. JCR Pharmaceuticals Co Ltd Recent Development Table 100. Orchard Therapeutics Plc Company Information Table 101. Orchard Therapeutics Plc Business Overview Table 102. Orchard Therapeutics Plc Alpha L-Iduronidase Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 103. Orchard Therapeutics Plc Alpha L-Iduronidase Product Portfolio Table 104. Orchard Therapeutics Plc Recent Development Table 105. Ossianix Inc Company Information Table 106. Ossianix Inc Business Overview Table 107. Ossianix Inc Alpha L-Iduronidase Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 108. Ossianix Inc Alpha L-Iduronidase Product Portfolio Table 109. Ossianix Inc Recent Development Table 110. Rain Bio Inc Company Information Table 111. Rain Bio Inc Business Overview Table 112. Rain Bio Inc Alpha L-Iduronidase Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 113. Rain Bio Inc Alpha L-Iduronidase Product Portfolio Table 114. Rain Bio Inc Recent Development Table 115. RegenxBio Inc Company Information Table 116. RegenxBio Inc Business Overview Table 117. RegenxBio Inc Alpha L-Iduronidase Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 118. RegenxBio Inc Alpha L-Iduronidase Product Portfolio Table 119. RegenxBio Inc Recent Development Table 120. Tega Therapeutics Inc Company Information Table 121. Tega Therapeutics Inc Business Overview Table 122. Tega Therapeutics Inc Alpha L-Iduronidase Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 123. Tega Therapeutics Inc Alpha L-Iduronidase Product Portfolio Table 124. Tega Therapeutics Inc Recent Development Table 125. Key Raw Materials Table 126. Raw Materials Key Suppliers Table 127. Alpha L-Iduronidase Distributors List Table 128. Alpha L-Iduronidase Customers List Table 129. Research Programs/Design for This Report Table 130. Authors List of This Report Table 131. Secondary Sources Table 132. Primary Sources List of Figures Figure 1. Alpha L-Iduronidase Product Image Figure 2. Global Alpha L-Iduronidase Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Alpha L-Iduronidase Sales Value (2021-2032) & (US$ Million) Figure 4. Global Alpha L-Iduronidase Sales (2021-2032) & (K Units) Figure 5. Global Alpha L-Iduronidase Sales Average Price (US$/Unit) & (2021-2032) Figure 6. Global Alpha L-Iduronidase Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. IDUA Image Figure 10. EC 3.2.1.76 Image Figure 11. Global Alpha L-Iduronidase Sales Volume by Type (2021 VS 2025 VS 2032) & (K Units) Figure 12. Global Alpha L-Iduronidase Sales Volume Share 2021 VS 2025 VS 2032 Figure 13. Global Alpha L-Iduronidase Sales Volume Share by Type (2021-2032) Figure 14. Global Alpha L-Iduronidase Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 15. Global Alpha L-Iduronidase Sales Value Share 2021 VS 2025 VS 2032 Figure 16. Global Alpha L-Iduronidase Sales Value Share by Type (2021-2032) Figure 17. Oncology Image Figure 18. Dermatology Image Figure 19. Immunology Image Figure 20. Musculoskeletal Disorders Image Figure 21. Global Alpha L-Iduronidase Sales Volume by Application (2021 VS 2025 VS 2032) & (K Units) Figure 22. Global Alpha L-Iduronidase Sales Volume Share 2021 VS 2025 VS 2032 Figure 23. Global Alpha L-Iduronidase Sales Volume Share by Application (2021-2032) Figure 24. Global Alpha L-Iduronidase Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 25. Global Alpha L-Iduronidase Sales Value Share 2021 VS 2025 VS 2032 Figure 26. Global Alpha L-Iduronidase Sales Value Share by Application (2021-2032) Figure 27. Global Alpha L-Iduronidase Sales by Region: 2021 VS 2025 VS 2032 (K Units) Figure 28. Global Alpha L-Iduronidase Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 29. Global Alpha L-Iduronidase Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 30. Global Alpha L-Iduronidase Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 31. North America Alpha L-Iduronidase Sales Value (2021-2032) & (US$ Million) Figure 32. North America Alpha L-Iduronidase Sales Value Share by Country (%), 2025 VS 2032 Figure 33. Europe Alpha L-Iduronidase Sales Value (2021-2032) & (US$ Million) Figure 34. Europe Alpha L-Iduronidase Sales Value Share by Country (%), 2025 VS 2032 Figure 35. Asia-Pacific Alpha L-Iduronidase Sales Value (2021-2032) & (US$ Million) Figure 36. Asia-Pacific Alpha L-Iduronidase Sales Value Share by Country (%), 2025 VS 2032 Figure 37. South America Alpha L-Iduronidase Sales Value (2021-2032) & (US$ Million) Figure 38. South America Alpha L-Iduronidase Sales Value Share by Country (%), 2025 VS 2032 Figure 39. Middle East & Africa Alpha L-Iduronidase Sales Value (2021-2032) & (US$ Million) Figure 40. Middle East & Africa Alpha L-Iduronidase Sales Value Share by Country (%), 2025 VS 2032 Figure 41. USA Alpha L-Iduronidase Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 42. USA Alpha L-Iduronidase Sales Value Share by Type, 2025 VS 2032 & (%) Figure 43. USA Alpha L-Iduronidase Sales Value Share by Application, 2025 VS 2032 & (%) Figure 44. Canada Alpha L-Iduronidase Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 45. Canada Alpha L-Iduronidase Sales Value Share by Type, 2025 VS 2032 & (%) Figure 46. Canada Alpha L-Iduronidase Sales Value Share by Application, 2025 VS 2032 & (%) Figure 47. Mexico Alpha L-Iduronidase Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 48. Mexico Alpha L-Iduronidase Sales Value Share by Type, 2025 VS 2032 & (%) Figure 49. Mexico Alpha L-Iduronidase Sales Value Share by Application, 2025 VS 2032 & (%) Figure 50. Germany Alpha L-Iduronidase Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 51. Germany Alpha L-Iduronidase Sales Value Share by Type, 2025 VS 2032 & (%) Figure 52. Germany Alpha L-Iduronidase Sales Value Share by Application, 2025 VS 2032 & (%) Figure 53. France Alpha L-Iduronidase Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 54. France Alpha L-Iduronidase Sales Value Share by Type, 2025 VS 2032 & (%) Figure 55. France Alpha L-Iduronidase Sales Value Share by Application, 2025 VS 2032 & (%) Figure 56. U.K. Alpha L-Iduronidase Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 57. U.K. Alpha L-Iduronidase Sales Value Share by Type, 2025 VS 2032 & (%) Figure 58. U.K. Alpha L-Iduronidase Sales Value Share by Application, 2025 VS 2032 & (%) Figure 59. Italy Alpha L-Iduronidase Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 60. Italy Alpha L-Iduronidase Sales Value Share by Type, 2025 VS 2032 & (%) Figure 61. Italy Alpha L-Iduronidase Sales Value Share by Application, 2025 VS 2032 & (%) Figure 62. Spain Alpha L-Iduronidase Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 63. Spain Alpha L-Iduronidase Sales Value Share by Type, 2025 VS 2032 & (%) Figure 64. Spain Alpha L-Iduronidase Sales Value Share by Application, 2025 VS 2032 & (%) Figure 65. Russia Alpha L-Iduronidase Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 66. Russia Alpha L-Iduronidase Sales Value Share by Type, 2025 VS 2032 & (%) Figure 67. Russia Alpha L-Iduronidase Sales Value Share by Application, 2025 VS 2032 & (%) Figure 68. Netherlands Alpha L-Iduronidase Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 69. Netherlands Alpha L-Iduronidase Sales Value Share by Type, 2025 VS 2032 & (%) Figure 70. Netherlands Alpha L-Iduronidase Sales Value Share by Application, 2025 VS 2032 & (%) Figure 71. Nordic Countries Alpha L-Iduronidase Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 72. Nordic Countries Alpha L-Iduronidase Sales Value Share by Type, 2025 VS 2032 & (%) Figure 73. Nordic Countries Alpha L-Iduronidase Sales Value Share by Application, 2025 VS 2032 & (%) Figure 74. China Alpha L-Iduronidase Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 75. China Alpha L-Iduronidase Sales Value Share by Type, 2025 VS 2032 & (%) Figure 76. China Alpha L-Iduronidase Sales Value Share by Application, 2025 VS 2032 & (%) Figure 77. Japan Alpha L-Iduronidase Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 78. Japan Alpha L-Iduronidase Sales Value Share by Type, 2025 VS 2032 & (%) Figure 79. Japan Alpha L-Iduronidase Sales Value Share by Application, 2025 VS 2032 & (%) Figure 80. South Korea Alpha L-Iduronidase Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 81. South Korea Alpha L-Iduronidase Sales Value Share by Type, 2025 VS 2032 & (%) Figure 82. South Korea Alpha L-Iduronidase Sales Value Share by Application, 2025 VS 2032 & (%) Figure 83. India Alpha L-Iduronidase Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 84. India Alpha L-Iduronidase Sales Value Share by Type, 2025 VS 2032 & (%) Figure 85. India Alpha L-Iduronidase Sales Value Share by Application, 2025 VS 2032 & (%) Figure 86. Australia Alpha L-Iduronidase Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 87. Australia Alpha L-Iduronidase Sales Value Share by Type, 2025 VS 2032 & (%) Figure 88. Australia Alpha L-Iduronidase Sales Value Share by Application, 2025 VS 2032 & (%) Figure 89. Southeast Asia Alpha L-Iduronidase Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 90. Southeast Asia Alpha L-Iduronidase Sales Value Share by Type, 2025 VS 2032 & (%) Figure 91. Southeast Asia Alpha L-Iduronidase Sales Value Share by Application, 2025 VS 2032 & (%) Figure 92. Brazil Alpha L-Iduronidase Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 93. Brazil Alpha L-Iduronidase Sales Value Share by Type, 2025 VS 2032 & (%) Figure 94. Brazil Alpha L-Iduronidase Sales Value Share by Application, 2025 VS 2032 & (%) Figure 95. Argentina Alpha L-Iduronidase Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 96. Argentina Alpha L-Iduronidase Sales Value Share by Type, 2025 VS 2032 & (%) Figure 97. Argentina Alpha L-Iduronidase Sales Value Share by Application, 2025 VS 2032 & (%) Figure 98. Chile Alpha L-Iduronidase Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 99. Chile Alpha L-Iduronidase Sales Value Share by Type, 2025 VS 2032 & (%) Figure 100. Chile Alpha L-Iduronidase Sales Value Share by Application, 2025 VS 2032 & (%) Figure 101. Colombia Alpha L-Iduronidase Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 102. Colombia Alpha L-Iduronidase Sales Value Share by Type, 2025 VS 2032 & (%) Figure 103. Colombia Alpha L-Iduronidase Sales Value Share by Application, 2025 VS 2032 & (%) Figure 104. Peru Alpha L-Iduronidase Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 105. Peru Alpha L-Iduronidase Sales Value Share by Type, 2025 VS 2032 & (%) Figure 106. Peru Alpha L-Iduronidase Sales Value Share by Application, 2025 VS 2032 & (%) Figure 107. Saudi Arabia Alpha L-Iduronidase Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 108. Saudi Arabia Alpha L-Iduronidase Sales Value Share by Type, 2025 VS 2032 & (%) Figure 109. Saudi Arabia Alpha L-Iduronidase Sales Value Share by Application, 2025 VS 2032 & (%) Figure 110. Israel Alpha L-Iduronidase Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 111. Israel Arabia Alpha L-Iduronidase Sales Value Share by Type, 2025 VS 2032 & (%) Figure 112. Israel Arabia Alpha L-Iduronidase Sales Value Share by Application, 2025 VS 2032 & (%) Figure 113. UAE Alpha L-Iduronidase Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 114. UAE Alpha L-Iduronidase Sales Value Share by Type, 2025 VS 2032 & (%) Figure 115. UAE Alpha L-Iduronidase Sales Value Share by Application, 2025 VS 2032 & (%) Figure 116. Turkey Alpha L-Iduronidase Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 117. Turkey Alpha L-Iduronidase Sales Value Share by Type, 2025 VS 2032 & (%) Figure 118. Turkey Alpha L-Iduronidase Sales Value Share by Application, 2025 VS 2032 & (%) Figure 119. Iran Alpha L-Iduronidase Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 120. Iran Alpha L-Iduronidase Sales Value Share by Type, 2025 VS 2032 & (%) Figure 121. Iran Alpha L-Iduronidase Sales Value Share by Application, 2025 VS 2032 & (%) Figure 122. Egypt Alpha L-Iduronidase Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 123. Egypt Alpha L-Iduronidase Sales Value Share by Type, 2025 VS 2032 & (%) Figure 124. Egypt Alpha L-Iduronidase Sales Value Share by Application, 2025 VS 2032 & (%) Figure 125. Alpha L-Iduronidase Value Chain Figure 126. Manufacturing Cost Structure Figure 127. Alpha L-Iduronidase Sales Mode & Process Figure 128. Direct Comparison with Distribution Share Figure 129. Distributors Profiles Figure 130. Years Considered Figure 131. Research Process Figure 132. Key Executives Interviewed

Scope & coverage.

Types
  • IDUA
  • EC 3.2.1.76
Applications
  • Oncology
  • Dermatology
  • Immunology
  • Musculoskeletal Disorders
Companies covered
  • ArmaGen Inc
  • BioStrategies LC
  • Denali Therapeutics Inc
  • EdiGene Inc
  • Gain Therapeutics Inc
  • Immusoft Corp
  • JCR Pharmaceuticals Co Ltd
  • Orchard Therapeutics Plc
  • Ossianix Inc
  • Rain Bio Inc
  • RegenxBio Inc
  • Tega Therapeutics Inc

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Alpha L-Iduronidase Sales Value (2021-2032)
  4. 1.2.2 Global Alpha L-Iduronidase Sales Volume (2021-2032)
  5. 1.2.3 Global Alpha L-Iduronidase Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Alpha L-Iduronidase Market Dynamics
  1. 2.1 Alpha L-Iduronidase Industry Trends
  2. 2.2 Alpha L-Iduronidase Industry Drivers
  3. 2.3 Alpha L-Iduronidase Industry Opportunities and Challenges
  4. 2.4 Alpha L-Iduronidase Industry Restraints
3 Alpha L-Iduronidase Market by Company
  1. 3.1 Global Alpha L-Iduronidase Company Revenue Ranking in 2025
  2. 3.2 Global Alpha L-Iduronidase Revenue by Company (2021-2026)
  3. 3.3 Global Alpha L-Iduronidase Sales Volume by Company (2021-2026)
  4. 3.4 Global Alpha L-Iduronidase Average Price by Company (2021-2026)
  5. 3.5 Global Alpha L-Iduronidase Company Ranking (2024-2026)
  6. 3.6 Global Alpha L-Iduronidase Company Manufacturing Base and Headquarters
  7. 3.7 Global Alpha L-Iduronidase Company Product Type and Application
  8. 3.8 Global Alpha L-Iduronidase Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Alpha L-Iduronidase Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Alpha L-Iduronidase Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Alpha L-Iduronidase Market by Type
  1. 4.1 Alpha L-Iduronidase Type Introduction
  2. 4.1.1 IDUA
  3. 4.1.2 EC 3.2.1.76
  4. 4.2 Global Alpha L-Iduronidase Sales Volume by Type
  5. 4.2.1 Global Alpha L-Iduronidase Sales Volume by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global Alpha L-Iduronidase Sales Volume by Type (2021-2032)
  7. 4.2.3 Global Alpha L-Iduronidase Sales Volume Share by Type (2021-2032)
  8. 4.3 Global Alpha L-Iduronidase Sales Value by Type
  9. 4.3.1 Global Alpha L-Iduronidase Sales Value by Type (2021 VS 2025 VS 2032)
  10. 4.3.2 Global Alpha L-Iduronidase Sales Value by Type (2021-2032)
  11. 4.3.3 Global Alpha L-Iduronidase Sales Value Share by Type (2021-2032)
5 Alpha L-Iduronidase Market by Application
  1. 5.1 Alpha L-Iduronidase Application Introduction
  2. 5.1.1 Oncology
  3. 5.1.2 Dermatology
  4. 5.1.3 Immunology
  5. 5.1.4 Musculoskeletal Disorders
  6. 5.2 Global Alpha L-Iduronidase Sales Volume by Application
  7. 5.2.1 Global Alpha L-Iduronidase Sales Volume by Application (2021 VS 2025 VS 2032)
  8. 5.2.2 Global Alpha L-Iduronidase Sales Volume by Application (2021-2032)
  9. 5.2.3 Global Alpha L-Iduronidase Sales Volume Share by Application (2021-2032)
  10. 5.3 Global Alpha L-Iduronidase Sales Value by Application
  11. 5.3.1 Global Alpha L-Iduronidase Sales Value by Application (2021 VS 2025 VS 2032)
  12. 5.3.2 Global Alpha L-Iduronidase Sales Value by Application (2021-2032)
  13. 5.3.3 Global Alpha L-Iduronidase Sales Value Share by Application (2021-2032)
6 Alpha L-Iduronidase Regional Sales and Value Analysis
  1. 6.1 Global Alpha L-Iduronidase Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Alpha L-Iduronidase Sales by Region (2021-2032)
  3. 6.2.1 Global Alpha L-Iduronidase Sales by Region: 2021-2026
  4. 6.2.2 Global Alpha L-Iduronidase Sales by Region (2027-2032)
  5. 6.3 Global Alpha L-Iduronidase Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Alpha L-Iduronidase Sales Value by Region (2021-2032)
  7. 6.4.1 Global Alpha L-Iduronidase Sales Value by Region: 2021-2026
  8. 6.4.2 Global Alpha L-Iduronidase Sales Value by Region (2027-2032)
  9. 6.5 Global Alpha L-Iduronidase Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Alpha L-Iduronidase Sales Value (2021-2032)
  12. 6.6.2 North America Alpha L-Iduronidase Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Alpha L-Iduronidase Sales Value (2021-2032)
  15. 6.7.2 Europe Alpha L-Iduronidase Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Alpha L-Iduronidase Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Alpha L-Iduronidase Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Alpha L-Iduronidase Sales Value (2021-2032)
  21. 6.9.2 South America Alpha L-Iduronidase Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Alpha L-Iduronidase Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Alpha L-Iduronidase Sales Value Share by Country, 2025 VS 2032
7 Alpha L-Iduronidase Country-level Sales and Value Analysis
  1. 7.1 Global Alpha L-Iduronidase Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Alpha L-Iduronidase Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Alpha L-Iduronidase Sales by Country (2021-2032)
  4. 7.3.1 Global Alpha L-Iduronidase Sales by Country (2021-2026)
  5. 7.3.2 Global Alpha L-Iduronidase Sales by Country (2027-2032)
  6. 7.4 Global Alpha L-Iduronidase Sales Value by Country (2021-2032)
  7. 7.4.1 Global Alpha L-Iduronidase Sales Value by Country (2021-2026)
  8. 7.4.2 Global Alpha L-Iduronidase Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Alpha L-Iduronidase Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Alpha L-Iduronidase Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Alpha L-Iduronidase Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Alpha L-Iduronidase Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Alpha L-Iduronidase Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Alpha L-Iduronidase Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Alpha L-Iduronidase Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Alpha L-Iduronidase Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Alpha L-Iduronidase Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Alpha L-Iduronidase Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Alpha L-Iduronidase Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Alpha L-Iduronidase Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Alpha L-Iduronidase Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Alpha L-Iduronidase Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Alpha L-Iduronidase Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Alpha L-Iduronidase Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Alpha L-Iduronidase Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Alpha L-Iduronidase Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Alpha L-Iduronidase Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Alpha L-Iduronidase Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Alpha L-Iduronidase Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Alpha L-Iduronidase Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Alpha L-Iduronidase Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Alpha L-Iduronidase Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Alpha L-Iduronidase Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Alpha L-Iduronidase Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Alpha L-Iduronidase Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Alpha L-Iduronidase Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Alpha L-Iduronidase Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Alpha L-Iduronidase Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Alpha L-Iduronidase Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Alpha L-Iduronidase Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Alpha L-Iduronidase Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Alpha L-Iduronidase Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Alpha L-Iduronidase Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Alpha L-Iduronidase Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Alpha L-Iduronidase Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Alpha L-Iduronidase Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Alpha L-Iduronidase Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Alpha L-Iduronidase Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Alpha L-Iduronidase Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Alpha L-Iduronidase Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Alpha L-Iduronidase Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Alpha L-Iduronidase Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Alpha L-Iduronidase Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Alpha L-Iduronidase Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Alpha L-Iduronidase Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Alpha L-Iduronidase Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Alpha L-Iduronidase Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Alpha L-Iduronidase Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Alpha L-Iduronidase Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Alpha L-Iduronidase Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Alpha L-Iduronidase Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Alpha L-Iduronidase Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Alpha L-Iduronidase Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Alpha L-Iduronidase Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Alpha L-Iduronidase Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Alpha L-Iduronidase Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Alpha L-Iduronidase Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Alpha L-Iduronidase Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Alpha L-Iduronidase Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Alpha L-Iduronidase Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Alpha L-Iduronidase Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Alpha L-Iduronidase Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Alpha L-Iduronidase Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Alpha L-Iduronidase Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Alpha L-Iduronidase Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Alpha L-Iduronidase Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Alpha L-Iduronidase Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Alpha L-Iduronidase Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Alpha L-Iduronidase Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Alpha L-Iduronidase Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Alpha L-Iduronidase Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Alpha L-Iduronidase Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Alpha L-Iduronidase Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Alpha L-Iduronidase Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Alpha L-Iduronidase Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Alpha L-Iduronidase Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Alpha L-Iduronidase Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Alpha L-Iduronidase Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Alpha L-Iduronidase Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Alpha L-Iduronidase Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Alpha L-Iduronidase Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Alpha L-Iduronidase Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 ArmaGen Inc
  2. 8.1.1 ArmaGen Inc Company Information
  3. 8.1.2 ArmaGen Inc Business Overview
  4. 8.1.3 ArmaGen Inc Alpha L-Iduronidase Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 ArmaGen Inc Alpha L-Iduronidase Product Portfolio
  6. 8.1.5 ArmaGen Inc Recent Developments
  7. 8.2 BioStrategies LC
  8. 8.2.1 BioStrategies LC Company Information
  9. 8.2.2 BioStrategies LC Business Overview
  10. 8.2.3 BioStrategies LC Alpha L-Iduronidase Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 BioStrategies LC Alpha L-Iduronidase Product Portfolio
  12. 8.2.5 BioStrategies LC Recent Developments
  13. 8.3 Denali Therapeutics Inc
  14. 8.3.1 Denali Therapeutics Inc Company Information
  15. 8.3.2 Denali Therapeutics Inc Business Overview
  16. 8.3.3 Denali Therapeutics Inc Alpha L-Iduronidase Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 Denali Therapeutics Inc Alpha L-Iduronidase Product Portfolio
  18. 8.3.5 Denali Therapeutics Inc Recent Developments
  19. 8.4 EdiGene Inc
  20. 8.4.1 EdiGene Inc Company Information
  21. 8.4.2 EdiGene Inc Business Overview
  22. 8.4.3 EdiGene Inc Alpha L-Iduronidase Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 EdiGene Inc Alpha L-Iduronidase Product Portfolio
  24. 8.4.5 EdiGene Inc Recent Developments
  25. 8.5 Gain Therapeutics Inc
  26. 8.5.1 Gain Therapeutics Inc Company Information
  27. 8.5.2 Gain Therapeutics Inc Business Overview
  28. 8.5.3 Gain Therapeutics Inc Alpha L-Iduronidase Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 Gain Therapeutics Inc Alpha L-Iduronidase Product Portfolio
  30. 8.5.5 Gain Therapeutics Inc Recent Developments
  31. 8.6 Immusoft Corp
  32. 8.6.1 Immusoft Corp Company Information
  33. 8.6.2 Immusoft Corp Business Overview
  34. 8.6.3 Immusoft Corp Alpha L-Iduronidase Sales, Value and Gross Margin (2021-2026)
  35. 8.6.4 Immusoft Corp Alpha L-Iduronidase Product Portfolio
  36. 8.6.5 Immusoft Corp Recent Developments
  37. 8.7 JCR Pharmaceuticals Co Ltd
  38. 8.7.1 JCR Pharmaceuticals Co Ltd Company Information
  39. 8.7.2 JCR Pharmaceuticals Co Ltd Business Overview
  40. 8.7.3 JCR Pharmaceuticals Co Ltd Alpha L-Iduronidase Sales, Value and Gross Margin (2021-2026)
  41. 8.7.4 JCR Pharmaceuticals Co Ltd Alpha L-Iduronidase Product Portfolio
  42. 8.7.5 JCR Pharmaceuticals Co Ltd Recent Developments
  43. 8.8 Orchard Therapeutics Plc
  44. 8.8.1 Orchard Therapeutics Plc Company Information
  45. 8.8.2 Orchard Therapeutics Plc Business Overview
  46. 8.8.3 Orchard Therapeutics Plc Alpha L-Iduronidase Sales, Value and Gross Margin (2021-2026)
  47. 8.8.4 Orchard Therapeutics Plc Alpha L-Iduronidase Product Portfolio
  48. 8.8.5 Orchard Therapeutics Plc Recent Developments
  49. 8.9 Ossianix Inc
  50. 8.9.1 Ossianix Inc Company Information
  51. 8.9.2 Ossianix Inc Business Overview
  52. 8.9.3 Ossianix Inc Alpha L-Iduronidase Sales, Value and Gross Margin (2021-2026)
  53. 8.9.4 Ossianix Inc Alpha L-Iduronidase Product Portfolio
  54. 8.9.5 Ossianix Inc Recent Developments
  55. 8.10 Rain Bio Inc
  56. 8.10.1 Rain Bio Inc Company Information
  57. 8.10.2 Rain Bio Inc Business Overview
  58. 8.10.3 Rain Bio Inc Alpha L-Iduronidase Sales, Value and Gross Margin (2021-2026)
  59. 8.10.4 Rain Bio Inc Alpha L-Iduronidase Product Portfolio
  60. 8.10.5 Rain Bio Inc Recent Developments
  61. 8.11 RegenxBio Inc
  62. 8.11.1 RegenxBio Inc Company Information
  63. 8.11.2 RegenxBio Inc Business Overview
  64. 8.11.3 RegenxBio Inc Alpha L-Iduronidase Sales, Value and Gross Margin (2021-2026)
  65. 8.11.4 RegenxBio Inc Alpha L-Iduronidase Product Portfolio
  66. 8.11.5 RegenxBio Inc Recent Developments
  67. 8.12 Tega Therapeutics Inc
  68. 8.12.1 Tega Therapeutics Inc Company Information
  69. 8.12.2 Tega Therapeutics Inc Business Overview
  70. 8.12.3 Tega Therapeutics Inc Alpha L-Iduronidase Sales, Value and Gross Margin (2021-2026)
  71. 8.12.4 Tega Therapeutics Inc Alpha L-Iduronidase Product Portfolio
  72. 8.12.5 Tega Therapeutics Inc Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Alpha L-Iduronidase Value Chain Analysis
  2. 9.1.1 Alpha L-Iduronidase Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Alpha L-Iduronidase Sales Mode & Process
  6. 9.2 Alpha L-Iduronidase Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Alpha L-Iduronidase Distributors
  9. 9.2.3 Alpha L-Iduronidase Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst